Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, JH Ji, O Voitko, A Poltoratskiy, S Ponce, F Verderame… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
…, O Voitko, A Poltoratskiy, S Ponce, F Verderame… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
Cancer patient-centered home care: a new model for health care in oncology
…, F Ferrau, N Borsellino, F Verderame… - … and clinical risk …, 2011 - Taylor & Francis
Patient-centered home care is a new model of assistance, which may be integrated with
more traditional hospital-centered care especially in selected groups of informed and trained …
more traditional hospital-centered care especially in selected groups of informed and trained …
[HTML][HTML] Virtual multidisciplinary tumor boards: a narrative review focused on lung cancer
To date, the virtual multidisciplinary tumor boards (vMTBs) are increasingly used to achieve
high-quality treatment recommendations across health-care regions, which expands and …
high-quality treatment recommendations across health-care regions, which expands and …
Spectra of polycrystalline phthalocyanines in the visible region
EA Lucia, FD Verderame - The Journal of Chemical Physics, 1968 - pubs.aip.org
Transmission spectra of sublimed thin films of the α‐crystalline forms of H2PC, CuPC, NiPC,
CoPC, and ZnPC in the 0.5 to 0.9‐μ region changed sharply as a result of α→ β …
CoPC, and ZnPC in the 0.5 to 0.9‐μ region changed sharply as a result of α→ β …
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment …
…, D Gasparro, C Ortega, M Tucci, F Verderame… - European urology, 2015 - Elsevier
Background The availability of new agents (NAs) active in patients with metastatic castration-
resistant prostate cancer (mCRPC) progressing after docetaxel treatment (abiraterone …
resistant prostate cancer (mCRPC) progressing after docetaxel treatment (abiraterone …
Durvalumab±tremelimumab+ platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
…, JH Ji, O Voitko, A Poltoratskiy, F Verderame… - 2020 - ascopubs.org
9002 Background: CASPIAN is an open-label, Phase 3 study of durvalumab
(D)±tremelimumab (T)+ etoposide and either cisplatin or carboplatin (EP) for pts with 1L ES …
(D)±tremelimumab (T)+ etoposide and either cisplatin or carboplatin (EP) for pts with 1L ES …
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme
…, C Giannitto Giorgio, MT Ionta, F Verderame… - BJU …, 2019 - Wiley Online Library
Objective To report the safety and efficacy results of patients enrolled in the Italian
Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods …
Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods …
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double …
…, A Savarese, S Pignata, F Verderame… - The lancet …, 2019 - thelancet.com
Background Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by
interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown …
interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown …
[HTML][HTML] Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer …
…, G Pellegriti, G Rinaldi, D Giuffrida, F Verderame… - European Journal of …, 2019 - Elsevier
Background Lenvatinib is a multi-kinase inhibitor approved for patients with radioactive
iodine (RAI)–resistant differentiated thyroid cancer (DTC). Before the drug approval from the …
iodine (RAI)–resistant differentiated thyroid cancer (DTC). Before the drug approval from the …